In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy

Abstract T-cell exhaustion remains a barrier to adoptive cell therapies. Although γc cytokines are used to expand T cells, their impact on T-cell states remains incompletely defined. Using an in vitro model of repetitive T-cell receptor stimulation, we found that high-dose interleukin 2 (IL2) or IL15 promoted exhausted CD8+ T-cell (TEX) differentiation, with increased inhibitory receptor expression and loss of stem-like features. During chronic lymphocytic choriomeningitis virus clone 13 infection, high IL2Rβ expression marked virus-specific CD8+ T cells with features of terminally exhausted T cells, whereas IL2Rβ deficiency favored progenitor-like populations. In TEX, IL2 and IL15 preferentially induced STAT5 phosphorylation over other signaling pathways. Genetic disruption of STAT5 similarly supported progenitor subsets, implicating STAT5 in the progression toward more differentiated TEX states under chronic stimulation. We therefore asked whether transient STAT5 attenuation during in vitro T-cell expansion could bias differentiation toward progenitor-like populations without compromising functional competence. Transient JAK3 or STAT5 inhibition enriched TCF1+Ly108+ progenitor–like cells while preserving cytokine production and degranulation capacity. Following transfer into tumor-bearing mice, cells expanded under STAT5-inhibited conditions mediated superior tumor control and prolonged survival. Likewise, transient STAT5 inhibition preserved memory–progenitor phenotypes in human CD22 chimeric antigen receptor T cells without impairing cytotoxicity. RNA sequencing of STAT5 inhibitor–expanded CD8+ T cells confirmed reinforced stem-like transcriptional programs and reduced enrichment of effector and exhausted signatures. Together, these findings identify the IL2Rβ–STAT5 axis as a regulator of CD8+ T-cell differentiation and support transient STAT5 modulation during ex vivo expansion to improve therapeutic T-cell products.